Company: ATHE
Filing Date: 2025-08-29
Form Type: 20-F
Source: 0001213900-25-082027
Chunk: 55

Company: ALTERITY THERAPEUTICS LTD
Filing Date: 2025-08-29
Form: 20-F
Item: Item 4
Chunk 55
---
 “Deep Learning Segmentation Improves Precision of Volume Assessment
                                              of Subcortical Structures in early MSA”                                           
--------------------------------------------------------------------------------------------------------------------------------

●   April 2022 - American Academy of Neurology, Title: “Iron Accumulation Correlates with Disease Severity in Patients with Multiple
                                                            System Atrophy”                                                         
------------------------------------------------------------------------------------------------------------------------------------

●   September 2021 - The International Parkinson and Movement Disorder Society Congress, Title: “Non-invasive imaging markers of
                                           iron accumulation in Multiple System Atrophy”                                        
--------------------------------------------------------------------------------------------------------------------------------

32

ATH434 Scientific Peer Validation

Scientific interest in ATH434 and validation of our approach to treating neurodegenerative diseases continue to grow, with data from ATH434 presented at global scientific and clinical conferences.

In November 2024, the peer-reviewed journal Metallomics published data on the importance of iron and iron-targeting agents like ATH434 to treat neurodegenerative diseases. The publication, entitled “ATH434, a promising iron-targeting compound for treating iron regulation disorders”, demonstrates the novel way in which ATH434 targets the labile, or reactive, form of iron which can be so damaging to cells when in excess. The iron binding properties of ATH434 presented in the publication support the characterization of ATH434 as an iron chaperone. The publication also describes how ATH434 targets the toxic form of iron that drives the pathology of a rare neurodegenerative disease known as Friedreich’s Ataxia. This toxic form of iron is also involved in the pathogenesis of Parkinson’s disease and MSA.

In October 2024, promising new data related to ATH434 were presented at the Society for Neuroscience 2024 that further the understanding of ATH434’s potential as a disease modifying treatment for neurodegenerative diseases, including Parkinson’s disease and related disorders. The poster presentation, entitled “Potent Antioxidant and Mitochondrial-protectant Effects of ATH434, a Novel Inhibitor of α-Synuclein Aggregation with Moderate Iron-binding Affinity,” demonstrated that the neuroprotective and mitochondrial protectant properties of ATH434 include reducing lipid damage in two distinct and disease-relevant neuronal injury models. ATH434’s antioxidant properties were distinguished from those of another iron binding agent approved for treating iron overload.

In November 2023, a poster was presented at the Society for Neuroscience, entitled: “Potent Antioxidant and Mitochondrial- protectant Effects of ATH434, a Novel Inhibitor of α-Synuclein Aggregation with Moderate Iron-